Clasp Therapeutics

Clasp Therapeutics, Inc. is a clinical-stage precision immuno-oncology company developing next-generation T cell engagers (TCEs) built on its proprietary pHLAre platform, which redirects T cells to mutant peptides — such as p53 R175H and mutant KRAS — presented by specific HLA molecules on the surface of tumor cells. The approach is intended to yield off-the-shelf, antibody-like medicines that hit common oncogenic driver mutations with tumor-exclusive specificity. Its lead candidate CLSP-1025 (p53 R175H / HLA-A*02:01) is in the Phase 1 GUARDIAN-101 trial (NCT06778863), and CLSP-5282, a first-in-class KRas-directed TCE, was unveiled at AACR 2026. Founded on research from Bert Vogelstein, Drew Pardoll and colleagues at Johns Hopkins, the company launched in March 2024 with $150 million led by Catalio Capital Management, Third Rock Ventures and Novo Holdings, and operates from Cambridge, Massachusetts and Rockville, Maryland. Clasp Therapeutics is a therapeutics developer and publishes no public API, developer program, SDK, or machine-readable specification.

Clasp Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Immuno-Oncology, Oncology, and Therapeutics.

Clasp Therapeutics’ developer surface includes engineering blog and 7 more developer resources.

🌐 Visit website 📡 Source on GitHub
8.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
0 APIs
CompanyBiotechnologyImmuno-OncologyOncologyTherapeuticsT Cell EngagersPrecision MedicineClinical StageLife Sciences

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 8.9/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.4 / 17
Commercial Clarity 1.8 / 17
Operational Transparency 0.0 / 11
Governance 0.0 / 10
Discoverability 4.9 / 9
Regulatory Posture 1.9 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/clasp-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Clasp Therapeutics Domain Security

TLSv1.3 · HSTS · DNSSEC · DMARC

SECURITY

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt
LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 4

The organization behind the API

Website
Website
 Blog
Blog
 BlogRSS
BlogRSS
 LinkedIn
LinkedIn

Other 1

Properties that don't map to a standard resource type

SecondaryMarketListing
SecondaryMarketListing

Source (apis.yml)

apis.yml Raw ↑ 
aid: clasp-therapeutics
name: Clasp Therapeutics
description: Clasp Therapeutics, Inc. is a clinical-stage precision immuno-oncology company developing next-generation T cell
  engagers (TCEs) built on its proprietary pHLAre platform, which redirects T cells to mutant peptides — such as p53 R175H
  and mutant KRAS — presented by specific HLA molecules on the surface of tumor cells. The approach is intended to yield off-the-shelf,
  antibody-like medicines that hit common oncogenic driver mutations with tumor-exclusive specificity. Its lead candidate
  CLSP-1025 (p53 R175H / HLA-A*02:01) is in the Phase 1 GUARDIAN-101 trial (NCT06778863), and CLSP-5282, a first-in-class
  KRas-directed TCE, was unveiled at AACR 2026. Founded on research from Bert Vogelstein, Drew Pardoll and colleagues at Johns
  Hopkins, the company launched in March 2024 with $150 million led by Catalio Capital Management, Third Rock Ventures and
  Novo Holdings, and operates from Cambridge, Massachusetts and Rockville, Maryland. Clasp Therapeutics is a therapeutics
  developer and publishes no public API, developer program, SDK, or machine-readable specification.
url: https://raw.githubusercontent.com/api-evangelist/clasp-therapeutics/refs/heads/main/apis.yml
image: http://static1.squarespace.com/static/65d6268f8ea1f7001e49412c/t/65dea444ac80a07c1b522dbc/1709089860325/Clasp-logo-white-RGB.png?format=1500w
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-09'
modified: '2026-08-09'
tags:
- Company
- Biotechnology
- Immuno-Oncology
- Oncology
- Therapeutics
- T Cell Engagers
- Precision Medicine
- Clinical Stage
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/clasp-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/clasp-therapeutics-llms.txt
- type: Website
  url: https://www.clasptx.com/
- type: Blog
  url: https://www.clasptx.com/press-release-publications
- type: BlogRSS
  url: https://www.clasptx.com/press-release-publications?format=rss
- type: PrivacyPolicy
  url: https://www.clasptx.com/privacy-policy
- type: LinkedIn
  url: https://www.linkedin.com/company/clasp-therapeutics/
- type: SecondaryMarketListing
  url: https://www.hiive.com/securities/clasp-therapeutics-stock
x-enrichment:
  date: '2026-08-09'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Clasp Therapeutics is a clinical-stage biotech whose product is a T cell engager drug candidate in a Phase 1 trial;
    its 41-URL Squarespace sitemap contains only leadership, founders, board, press-release and privacy-policy pages, and
    no api./developer./docs. subdomain resolves in DNS.
  evidence:
  - url: https://www.clasptx.com/sitemap.xml
    status: 200
  - url: https://www.clasptx.com/openapi.json
    status: 404
  - url: https://www.clasptx.com/developers
    status: 404
  - url: https://www.clasptx.com/graphql
    status: 404
  - url: https://www.clasptx.com/llms.txt
    status: 404
  - url: https://www.clasptx.com/.well-known/agent-card.json
    status: 404
  - url: https://www.clasptx.com/.well-known/security.txt
    status: 404
  checked: '2026-08-09'